Lv5
1286 积分 2025-02-28 加入
Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021
10小时前
已完结
Biology of brain metastases and novel targeted therapies: Time to translate the research
1天前
已完结
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
1天前
已完结
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases
1天前
已完结
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
6天前
已完结
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study
6天前
已关闭
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
8天前
已完结
Predictive Value of PIK3CA Mutations for Response to CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
8天前
已完结
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients
8天前
已完结
皖公网安备34019202002308
